$1.06 Billion is the total value of Omega Fund Management, LLC's 24 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 26.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVB | New | Nuvation Bio | $294,819,000 | – | 28,212,376 | +100.0% | 27.89% | – |
| REPL | Sell | Replimune Group | $152,802,000 | -21.1% | 5,008,245 | -1.3% | 14.45% | -50.2% |
| MORF | Sell | Morphic Holding | $143,802,000 | +46.7% | 2,272,478 | -22.2% | 13.60% | -7.5% |
| KRON | Kronos Bio | $111,761,000 | -2.0% | 3,818,283 | 0.0% | 10.57% | -38.2% | |
| IKNA | New | Ikena Oncology | $63,538,000 | – | 2,249,123 | +100.0% | 6.01% | – |
| AVIR | Atea Pharmaceuticals | $52,315,000 | +47.8% | 847,208 | 0.0% | 4.95% | -6.8% | |
| SPRB | Spruce Biosciences | $35,873,000 | -31.7% | 2,161,022 | 0.0% | 3.39% | -56.9% | |
| GOSS | Gossamer Bio | $30,716,000 | -4.3% | 3,320,608 | 0.0% | 2.90% | -39.7% | |
| IMUX | Immunic | $28,503,000 | +4.3% | 1,788,160 | 0.0% | 2.70% | -34.2% | |
| SANA | New | Sana Biotechnology, Inc. | $28,240,000 | – | 843,750 | +100.0% | 2.67% | – |
| PRTK | Paratek Pharmaceuticals | $18,359,000 | +12.8% | 2,600,410 | 0.0% | 1.74% | -28.8% | |
| ARQT | Sell | Arcutis Biothereapeutics | $18,048,000 | +0.2% | 623,836 | -2.6% | 1.71% | -36.8% |
| CMPI | Checkmate Pharmaceuticals | $16,208,000 | -16.8% | 1,335,050 | 0.0% | 1.53% | -47.5% | |
| ALPN | Alpine Immune Sciences | $13,620,000 | -15.9% | 1,284,900 | 0.0% | 1.29% | -47.0% | |
| SYRS | Syros Pharmaceuticals | $11,688,000 | -31.1% | 1,562,500 | 0.0% | 1.11% | -56.5% | |
| EPIX | Sell | ESSA Pharma | $9,786,000 | +16.2% | 336,869 | -52.3% | 0.93% | -26.6% |
| CDTX | Cidara Therapeutics | $5,334,000 | +33.0% | 2,005,249 | 0.0% | 0.50% | -16.0% | |
| OMEG | New | Omega Alpha SPACclass a ordinary shares | $5,000,000 | – | 501,000 | +100.0% | 0.47% | – |
| FGEN | FibroGen | $4,535,000 | -6.4% | 130,646 | 0.0% | 0.43% | -41.0% | |
| TRVI | Trevi Therapeutics | $3,424,000 | +2.8% | 1,263,408 | 0.0% | 0.32% | -35.1% | |
| OBSV | ObsEva | $3,248,000 | +56.2% | 999,364 | 0.0% | 0.31% | -1.6% | |
| JNCE | Sell | Jounce Therapeutics | $2,830,000 | +20.7% | 275,513 | -17.7% | 0.27% | -23.9% |
| IMCR | New | Immunocore Holdings | $2,194,000 | – | 51,535 | +100.0% | 0.21% | – |
| PIRS | Sell | Pieris Pharmaceuticals | $580,000 | -69.1% | 225,741 | -69.9% | 0.06% | -80.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.